Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 3/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 7/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.44 |
| ▸ | USP2 | O75604 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15214193 | 0.92 | SLC29A1 (0.46) | ADORA2ASLC29A1PIK3CDLMNAALDH1A1 | |
| SCHEMBL1312875 | 0.81 | HPGD (0.48) | ADORA2ASLC29A1PIK3CDUSP2ALDH1A1 | |
| SCHEMBL12112236 | 0.81 | PIK3CD (0.47) | ADORA2APIK3CDLMNAADORA1TSHR | |
| SCHEMBL16123777 | 0.80 | PIK3CD (0.41) | ADORA2APIK3CDLMNAALDH1A1ADORA1 | |
| SCHEMBL13394115 | 0.80 | PIK3CD (0.41) | ADORA2APIK3CDLMNAALDH1A1ADORA1 | |
| SCHEMBL1313539 | 0.79 | HPGD (0.53) | ADORA2ASLC29A1USP2ALDH1A1MEN1 | |
| SCHEMBL12112237 | 0.79 | PDE4A (0.42) | ADORA2APIK3CDLMNAADORA1TSHR | |
| SCHEMBL12112231 | 0.79 | PIK3CD (0.38) | ADORA2APIK3CDLMNAADORA1YTHDC1 | |
| SCHEMBL12112232 | 0.79 | PIK3CD (0.39) | ADORA2APIK3CD | |
| SCHEMBL12112229 | 0.79 | SLC29A1 (0.43) | ADORA2ASLC29A1PIK3CDLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-03 | — | — | US | disclosed |
| US-9322831-B2 | DDX3 as a biomarker for cancer and methods related thereto | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2014149084-A2 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | THE JOHNS HOPKINS UNIVERSITY | 2013-10-24 | — | — | US | disclosed |
| US-8518901-B2 | Fused diimidazodiazepine compounds and methods of use and manufacture thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-08-27 | — | — | US | disclosed |
| US-8518901-B2 | Fused diimidazodiazepine compounds and methods of use and manufacture thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | HOSMANE, RAMACHANDRA S. | 2011-11-10 | — | — | US | disclosed |
| WO-2010039187-A2 | FUSED DIIMIDAZODIAZEPINE COMPOUNDS AND METHODS OF USE AND MANUFACTURE THEREOF | UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160319366-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | DDX3X, DDB1, DDX24 | ADORA2A 4578/4885SLC29A1 2701/4885PIK3CD 2000/4885 |
| US-20110275588-A1 | Fused Diimidazodiazepine Compounds and Methods of Use and Manufacture Thereof | IKZF3, AADAC, IKBKE | ADORA2A 2862/4885SLC29A1 3265/4885PIK3CD 2306/4885 |
| US-20130281440-A1 | DDX3 AS A BIOMARKER FOR CANCER AND METHODS RELATED THERETO | DDX3X, DDB1, DDX24 | ADORA2A 4578/4885SLC29A1 2701/4885PIK3CD 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.